EHA 2018: Inhibitor Plus Chemotherapy May Improve Outcomes in Younger Patients With FLT3-Mutant Acute Myeloid Leukemia.
Outcomes in younger patients with newly diagnosed FLT3-mutant acute myeloid leukemia (AML) may be improved by adding a potent pan-FLT3 inhibitor to chemotherapy, according to the new research findings presented at the 23rd Congress of the European Hematology Association (EHA), which took place from June 14 to 17, 2018. This study assessed the outcomes of a […]
